Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insight Molecular Diagnostics's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.29.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.01.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 44.70% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 36.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Insight Molecular Diagnostics's EPS without NRI or its related term are showing as below:
LTS:0KCC'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -1.3 Med: 11.55 Max: 44.7
Current: 44.7
During the past 13 years, Insight Molecular Diagnostics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 44.70% per year. The lowest was -1.30% per year. And the median was 11.55% per year.
LTS:0KCC's 3-Year EPS without NRI Growth Rate is ranked better than 78.62% of 159
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8
vs LTS:0KCC: 44.70
Insight Molecular Diagnostics (LTS:0KCC) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Insight Molecular Diagnostics EPS without NRI Related Terms
Insight Molecular Diagnostics EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics EPS without NRI Chart
LTS:0KCC vs XGN, BDSX, BNR: EPS without NRI Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's PE Ratio without NRI falls into.
Insight Molecular Diagnostics EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (LTS:0KCC) has a EPS without NRI of $-1.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #34 out of 159 companies in the Medical Diagnostics & Research industry, placing it in the top 21.4%.
Is Insight Molecular Diagnostics' EPS without NRI too high?
Insight Molecular Diagnostics' current EPS without NRI is $-1.01. Based on the distribution chart, Insight Molecular Diagnostics ranks #34 out of 159 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' EPS without NRI compare to XGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #34 out of 159 companies for EPS without NRI. This places Insight Molecular Diagnostics in the top 21% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current EPS without NRI is $-1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (LTS:0KCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $4.51 — trading 258% above its estimated fair value. The current EPS without NRI is $-1.01. Insight Molecular Diagnostics' overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Insight Molecular Diagnostics (LTS:0KCC), the current EPS without NRI is $-1.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (LTS:0KCC) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $4.51 is trading 258% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for LTS:0KCC:
EPS without NRI: $-1.01
GF Value™: $1.26 vs. price of $4.51 (258% above fair value)
No single metric tells the full story. See the LTS:0KCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
52GF Score
Get the complete analysis for LTS:0KCC
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCC has been successfully added to your 
